Sysmex (OTCMKTS:SSMXY) Sets New 12-Month Low – Time to Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as $8.01 and last traded at $8.2348, with a volume of 309220 shares. The stock had previously closed at $8.53.

Wall Street Analysts Forecast Growth

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Sysmex Price Performance

The stock has a market capitalization of $5.27 billion, a PE ratio of 22.03 and a beta of 1.10. The firm’s fifty day moving average price is $8.71 and its two-hundred day moving average price is $9.10. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last issued its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The company had revenue of $877.92 million during the quarter, compared to analysts’ expectations of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, equities analysts predict that Sysmex Corporation ADR will post 0.42 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.